The trial was conducted by European Organisation for the Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC). Primary endpoint of the study
Plethora intends to run the two pivotal studies in parallel, one in the US and one in Europe. Each will be a multi-center, randomized, double-blind, placebo-controlled efficacy study
The transaction includes warrants to purchase up to 1,145,259 shares of Dusa’s common stock at an exercise price of $2.85 per share. The warrants will expire on April
Mirapex (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. The company believes that it is the first to file
The acquisition provides Nycomed US with additional branded dermatologics to build on its PharmaDerm division and the opportunity to enhance its platform for acquisition, in-licensing and co-promotion. Nycomed
The device was invented by two retinal surgeons who serve as clinical advisors to Opko. Samuel Reich, executive vice president of ophthalmologics at Opko, said: “Experts are raising
Through the proposed license agreement, Taisho would grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. If the license agreement is signed, Taisho will receive
The pending patent covers therapeutic agents that are used in conjunction with radiation therapy to improve the efficiency and specificity of radiation for oncology. The agents, called radiosensitizers,
Following the agreement, Lilly will acquire the rights to a portfolio of transient receptor potential vanilloid sub-family 1 antagonist molecules, including a clinical compound, GRC 6211 that is
This is the first patent awarded to the company for skin lightening technology. The company’s patented technology uses small molecule inhibitors to regulate a key enzyme within skin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.